prognosi
patient
acut
myeloid
leukemia
primari
treatment
fail
remain
poor
order
improv
patient
outcom
conduct
phase
prospect
multicent
trial
test
feasibl
new
sequenti
regimen
combin
short
cours
intens
chemotherapi
reduc
intensitycondit
regimen
allogen
stemcel
transplant
twentyfour
patient
median
age
year
acut
myeloid
leukemia
primari
treatment
failur
includ
cytogenet
risk
poor
patient
intermedi
nine
sequenti
regimen
consist
clofarabin
mgm
day
cytosin
arabinosid
gm
day
day
follow
rest
reducedintens
condit
allogen
stemcel
transplant
combin
cyclophosphamid
mgkg
intraven
busulfan
mgkgday
day
antithymocyt
globulin
mgkgday
day
patient
complet
remiss
day
receiv
prophylact
donor
lymphocyt
infus
eighteen
patient
achiev
complet
remiss
median
followup
month
kaplanmei
estim
overal
surviv
ci
year
ci
year
kaplanmei
estim
leukemiafre
surviv
ci
year
ci
year
cumul
incid
nonrelaps
mortal
ci
year
ci
year
result
phase
prospect
multicent
trial
endors
safeti
efficaci
clofarabinebas
sequenti
reducedtox
condit
regimen
warrant
investig
studi
regist
wwwclinicaltrialsgov
identifi
number
abstract
ferrata
storti
foundat
prognosi
patient
acut
myeloid
leukemia
aml
primari
treatment
failur
remain
poor
primari
treatment
failur
primari
refractori
aml
defin
failur
achiev
complet
hematolog
remiss
cr
one
two
cours
induct
chemotherapi
patient
chanc
achiev
cr
anoth
standard
convent
treatment
includ
use
intermediateor
highdos
cytosin
arabinosid
arac
alon
combin
sequenti
regimen
clofarabin
cytosin
arabinosid
reducedintens
condit
transplant
primari
refractori
acut
myeloid
leukemia
anthracyclin
fludarabin
gemtuzumabozogamicin
best
overal
surviv
rate
year
less
median
surviv
less
month
light
poor
result
convent
chemotherapi
allogen
stem
cell
transplant
sct
repres
potenti
therapeut
tool
treatment
patient
refractori
aml
howev
standard
myeloabl
condit
mac
combin
cyclophosphamid
either
total
bodi
irradi
busulfan
associ
high
day
overal
mortal
rate
around
refractori
aml
patient
preclud
use
reducedintens
condit
ric
regimen
allow
signific
reduct
nonrelaps
mortal
nrm
expand
transplant
option
patient
inelig
standard
mac
allogen
sct
ric
regimen
aim
take
advantag
graftversusleukemia
gvl
effect
mediat
donor
immunocompet
cell
rather
upfront
cytoreduct
effect
condit
chemotherapi
howev
refractori
aml
ric
may
control
diseas
suffici
allow
gvl
effect
occur
attempt
overcom
problem
socal
sequenti
transplant
approach
develop
combin
short
intens
cours
salvag
chemotherapi
decreas
leukemia
cell
burden
ric
result
achiev
sequenti
flamsa
strategi
fludarabin
intermedi
dose
arac
amsacrin
follow
gy
total
bodi
irradi
cyclophosphamid
antithymocyt
globulin
develop
munich
group
among
promis
publish
far
howev
result
still
unsatisfactori
term
relaps
incid
longterm
leukemia
control
high
incid
sever
toxic
relat
amsacrin
mainli
cardiotox
total
bodi
irradi
hamper
overal
safeti
success
procedur
strategi
improv
sequenti
approach
warrant
improv
could
made
possibl
avoid
amsacrin
use
clofarabin
intraven
iv
busulfan
replac
fludarabin
total
bodi
irradi
respect
clofarabin
nextgener
purin
analog
signific
antileukem
activ
particulari
relaps
aml
acut
lymphoblast
leukemia
found
ric
regimen
combin
clofarabin
bulsulfan
antithymocyt
globulin
safe
nrm
rate
allow
effici
diseas
control
aml
patient
cr
thu
use
clofarabin
altern
fludarabin
set
ric
allogen
sct
appear
attract
hand
antileukem
activ
bulsulfan
wide
recogn
favor
safeti
profil
associ
use
iv
bulsufan
well
establish
therefor
conduct
multicent
prospect
phase
studi
aim
assess
efficaci
sequenti
regimen
combin
short
cours
intens
chemotherapi
base
clofarabin
arac
ric
allogen
sct
cyclophosphamid
iv
busulfan
antithymocyt
globulin
follow
delay
prophylact
donor
lymphocyt
infus
pdli
patient
aml
primari
treatment
failur
prospect
multicentr
phase
studi
includ
patient
diagnos
aml
primari
treatment
failur
underw
allogen
sct
trial
approv
particip
center
institut
review
board
de
protect
de
personn
de
tour
cpp
ref
nation
agenc
de
sanitair
de
produit
de
afssap
studi
regist
clinicaltrialsgov
identifi
number
inform
consent
patient
donor
obtain
inclus
studi
patient
age
year
elig
studi
confirm
diagnosi
aml
statu
primari
induct
failur
ie
patient
aliv
induct
treatment
fail
fulfil
criteria
cr
cr
incomplet
recoveri
defin
either
persist
leukem
blast
peripher
blood
persist
leukem
blast
repres
bone
marrow
aspir
second
cours
induct
chemotherapi
ii
persist
hypoplasia
defin
hypocellular
bone
marrow
incomplet
reconstitut
cell
count
peripher
blood
ie
absolut
neutrophil
count
l
platelet
count
l
day
start
chemotherapi
induct
chemotherapi
administ
accord
particip
institut
prefer
addit
inclus
criteria
avail
match
sibl
donor
unrel
stemcel
donor
match
singl
hla
antigen
allel
mismatch
exclus
criteria
document
chloroma
leukem
infiltr
central
nervou
system
aml
karnofski
perform
score
serum
creatinin
mgdl
creatinin
clearanc
less
mlmin
bilirubin
mgdl
aminotransferas
alkalin
phosphatas
time
upper
normal
limit
acut
chronic
heart
failur
pregnanc
patient
includ
studi
proceed
directli
sequenti
allogen
sct
howev
addit
cytoreduct
chemotherapi
treat
physician
discret
allow
control
leukem
prolifer
prepar
allogen
sct
ongo
prepar
regimen
consist
mgm
day
clofarabin
gm
day
arac
consecut
day
day
rest
mgkg
cyclophosphamid
day
day
mgkgday
iv
busulfan
consecut
day
day
mgkgday
antithymocyt
globulin
consecut
day
day
figur
patient
receiv
treatment
inpati
privat
room
remain
hospit
hematopoiet
recoveri
day
design
day
graft
infus
support
care
antimicrobi
prophylaxi
report
previous
note
support
care
manag
cytomegaloviru
infect
homogen
period
studi
blood
product
filter
irradi
screen
cytomegaloviru
first
day
transplant
patient
assess
least
week
cytomegaloviru
reactiv
order
initi
preemptiv
ganciclovir
therapi
necessari
graftversushost
diseas
gvhd
prophylaxi
patient
given
either
cyclosporin
alon
case
hlamatch
sibl
donor
cyclosporin
mycophenol
mofetil
case
hlamatch
unrel
donor
per
protocol
dose
mycophenol
mofetil
decreas
progress
week
start
day
cyclosporin
day
stop
day
gvhd
appear
patient
receiv
pdli
cr
absenc
histori
grade
iiiv
gvhd
day
without
immunosuppress
therapi
free
activ
infect
document
donor
cell
chimer
peripher
blood
sequenti
ric
allosct
refractori
aml
haematologica
cell
first
pdli
given
day
day
discontinu
immunosuppress
initi
dose
cellskg
patient
match
sibl
donor
cellskg
unrel
donor
absenc
gvhd
pdli
dose
escal
increasetransfus
three
time
everi
week
donorrecipi
pair
type
allel
level
singl
hla
mismatch
ten
hlaa
hlab
hlacw
allow
antigen
allel
level
graft
sourc
granulocyt
colonystimul
factormobil
peripher
blood
stem
cell
graft
sourc
recommend
per
protocol
unmanipul
bone
marrow
accept
peripher
blood
stem
cell
avail
overal
surviv
rate
year
transplant
primari
endpoint
secondari
endpoint
includ
engraft
leukemiafre
surviv
leukemia
respons
rate
remiss
statu
relaps
rate
treatmentrel
toxic
nrm
discontinu
immunossupress
therapi
pdli
acut
gvhd
chronic
gvhd
time
neutrophil
recoveri
defin
first
consecut
day
absolut
neutrophil
count
exceed
l
engraft
failur
absolut
neutrophil
count
l
day
allogen
sct
leukemia
respons
rate
evalu
day
month
transplant
gvhd
evalu
accord
seattl
standard
criteria
hypothesi
primari
endpoint
improv
overal
surviv
year
use
one
step
ahern
procedur
patient
would
need
statist
analysi
meaning
inclus
patient
plan
order
take
account
possibl
drop
out
inclus
ie
patient
would
receiv
transplant
due
infect
event
occur
identif
donor
etc
start
condit
number
surviv
patient
seven
hypothesi
overal
surviv
rate
less
reject
target
error
rate
number
surviv
patient
year
six
less
hypothesi
overal
surviv
reject
target
error
rate
overal
leukemiafre
surviv
rate
calcul
use
kaplanmei
method
overal
surviv
defin
time
allogen
sct
death
regardless
caus
leukemiafre
surviv
defin
surviv
evid
leukemia
achiev
complet
remiss
probabl
nrm
calcul
use
cumul
incid
procedur
defin
nrm
death
evid
leukemia
relaps
progress
data
comput
use
spss
ezr
version
saitama
medic
center
jichi
medic
univers
japan
graphic
user
interfac
r
r
foundat
statist
comput
version
characterist
patient
donor
summar
tabl
median
age
recipi
year
rang
one
patient
age
year
includ
trial
approv
protocol
steer
committe
aml
cytogenet
statu
classifi
accord
european
leukemia
net
intermedi
patient
advers
patient
aml
favor
cytogenet
seven
patient
secondari
aml
secondari
myelodysplast
syndrom
other
malign
treat
chemotherapi
radiotherapi
duval
score
six
patient
five
patient
six
patient
seven
patient
diagnosi
aml
primari
induct
failur
confirm
persist
second
cours
induct
chemotherapi
leukem
blast
peripher
blood
two
patient
leukem
blast
bone
marrow
patient
one
patient
persist
hypoplasia
besid
patient
persist
hypoplasia
median
marrow
blast
percentag
transplant
rang
fifteen
donor
hlaident
sibl
nine
unrel
donor
stem
cell
sourc
bone
marrow
one
case
peripher
blood
stem
cell
remain
patient
karnofski
score
wherea
patient
develop
pancytopenia
sequenti
condit
regimen
twentytwo
engraft
two
die
aplasia
median
time
neutrophil
recoveri
day
rang
median
time
platelet
recoveri
l
day
rang
chimer
evalu
cell
day
full
donor
chimer
donor
cell
found
patient
eight
patient
mix
chimer
grade
iiiv
acut
gvhd
develop
four
patient
three
grade
ii
diseas
day
one
grade
iii
gvhd
day
transplant
patient
develop
grade
iv
acut
gvhd
skin
gut
liver
affect
three
three
one
patient
respect
acut
gvhd
resolv
patient
upon
corticosteroid
treatment
chronic
gvhd
develop
nine
patient
five
limit
diseas
four
extens
chronic
gvhd
septicemia
encount
nine
patient
caus
bacteria
seven
candida
albican
two
septicemia
led
sepsi
septic
shock
three
patient
eight
patient
develop
pneumonia
caus
aspergillu
spp
three
patient
bacteria
two
virus
two
unknown
etiolog
one
patient
besid
viral
pneumonia
two
patient
cytomegaloviru
reactiv
two
epsteinbarr
viru
reactiv
one
corona
viru
infect
one
patient
bk
virusassoci
hemorrhag
cystiti
nonhematolog
side
effect
relat
gvhd
infect
classifi
accord
world
health
organ
criteria
fifteen
grade
iii
advers
event
report
patient
grade
iv
advers
event
occur
studi
tabl
protocolrel
grade
iiiiv
hematolog
advers
event
report
five
patient
includ
neutropenia
grade
iii
grade
iv
lymphopenia
grade
iii
grade
iv
anemia
grade
iii
bone
marrow
failur
grade
iii
pancytopenia
grade
iii
patient
one
sever
hematolog
advers
event
day
patient
evalu
respons
one
patient
die
eighteen
patient
cr
five
persist
leukemia
tabl
one
patient
persist
diseas
day
achiev
cr
day
without
treatment
besid
reduct
immunosuppress
therapi
maintain
last
followup
diseas
relaps
achiev
cr
occur
ten
patient
median
day
rang
allogen
sct
overal
median
followup
transplant
month
rang
among
surviv
patient
patient
includ
studi
die
seven
still
aliv
last
followup
kaplanmei
estim
overal
surviv
leukemiafre
surviv
year
ci
ci
figur
b
thirteen
death
directli
attribut
diseas
progress
relaps
wherea
four
case
relat
transplant
two
relat
infect
two
chronic
gvhd
year
cumul
incid
relapseprogress
nrm
ci
ci
respect
figur
six
patient
receiv
dli
studi
includ
three
patient
fulfil
criteria
pdli
three
addit
patient
receiv
dli
day
without
immunosuppress
therapi
mix
chimer
although
pdli
could
given
day
patient
receiv
first
dose
day
due
delay
cyclosporin
withdraw
patient
mix
chimer
receiv
first
dli
dose
earlier
day
overal
three
patient
receiv
one
transfus
two
receiv
two
transfus
one
receiv
three
transfus
escal
dose
dli
group
patient
receiv
fewer
three
transfus
relaps
develop
gvhd
leukem
relaps
occur
one
patient
pdli
two
dli
mix
chimer
caus
death
three
gvhd
main
complic
dli
grade
ii
acut
gvhd
develop
one
patient
dli
mix
chimer
chronic
gvhd
three
patient
receiv
pdli
one
dli
mix
chimer
one
patient
die
extens
chronic
gvhd
pdli
last
followup
two
patient
cmv
cytomegaloviru
pbsc
peripher
blood
stem
cell
tnc
total
nucleat
cell
one
patient
age
year
includ
trial
approv
protocol
steer
committe
one
patient
persist
bm
hypoplasia
marrow
blast
evalu
two
patient
bm
blast
evalu
given
high
number
circul
blast
four
patient
donor
singl
antigen
allel
mismatch
cell
dose
indic
patient
receiv
pbsc
patient
receiv
bm
receiv
kg
tnc
kg
cell
aliv
cr
dli
mix
chimer
three
patient
success
convert
full
donor
chimer
among
patient
aliv
day
reason
give
pdli
diseas
progress
relaps
histori
grade
iiiv
acut
gvhd
current
chronic
gvhd
infect
refus
donor
patient
decis
physician
charg
patient
histori
grade
acut
gvhd
sequenti
transplant
approach
combin
short
cours
intens
chemotherapi
base
clofarabin
arac
ric
allogen
sct
evalu
current
phase
prospect
studi
success
fulfil
object
achiev
limit
toxic
retain
substanti
antileukemia
activ
heavili
pretreat
popul
receiv
two
induct
chemotherapi
cours
median
age
year
rang
karnofski
score
patient
found
nrm
rate
grade
iv
nonhematolog
advers
event
favor
compar
standard
mac
regimen
also
sequenti
flamsa
strategi
longterm
updat
flamsa
studi
schmidt
et
al
report
nrm
incid
consist
report
evalu
flamsa
strategi
retrospect
studi
recent
report
nrm
incid
allogen
sct
aml
primari
induct
failur
signific
differ
accord
multivari
analysi
nrm
patient
treat
mac
ric
flamsa
regimen
thu
approach
avoid
amsacrin
replac
fludarabin
total
bodi
irradi
clofarabin
iv
bulsufan
respect
fulfil
object
decreas
toxic
low
incid
nrm
compar
observ
reduc
toxic
regimen
base
fludarabin
iv
busulfan
decreas
toxic
achiev
expens
less
antitumor
efficaci
sequenti
condit
regimen
approach
still
exert
antileukem
effect
patient
aml
primari
treatment
failur
achiev
cr
day
transplant
may
appear
lower
cr
rate
achiev
day
use
flamsa
approach
howev
latter
studi
includ
patient
refractori
relaps
aml
patient
alreadi
cr
allogen
sct
studi
contrast
trial
patient
primari
refractori
aml
therefor
activ
diseas
time
transplant
furthermor
patient
unfavor
cytogenet
secondari
aml
thu
sequenti
approach
mohti
et
al
haematologica
significantli
enhanc
antileukem
effect
compar
ric
allogen
sct
patient
activ
aml
achiev
cr
overal
surviv
rate
similar
report
schmid
et
al
use
flamsa
sequenti
regimen
superior
report
standard
mac
allogen
sct
similarli
middek
et
al
report
overal
surviv
rate
relapsedrefractori
aml
clofarabin
salvag
therapi
allogen
sct
patient
achiev
respons
despit
encourag
result
relaps
remain
princip
complic
lead
leukemiafre
surviv
rate
acknowledg
surviv
curv
reach
plateau
relaps
may
continu
occur
howev
persist
cr
year
highrisk
patient
import
achiev
sinc
retreat
possibl
late
relaps
note
longer
interv
transplant
relaps
associ
improv
surviv
studi
design
decreas
relaps
risk
patient
achiev
cr
plan
pdli
infus
howev
among
patient
aliv
day
minor
six
patient
receiv
dli
studi
earli
diseas
relapseprogress
histori
gvhd
furthermor
among
patient
treat
dli
half
die
relaps
use
dli
enhanc
antileukem
effect
decreas
relaps
studi
therefor
disappoint
strategi
addit
previous
describ
observ
rel
high
incid
gvhd
pdli
therefor
seem
indispens
develop
new
strategi
prevent
relaps
allogen
sct
one
way
overcom
difficulti
would
perform
earlier
pdli
patient
still
immunosuppress
therapi
furthermor
goodyear
et
al
report
earli
administr
hypomethyl
agent
azacytidin
aml
patient
ferrata
storti
foundat
well
toler
associ
low
incid
gvhd
strategi
appear
promis
prospect
trial
evalu
preemptiv
azacytidin
dli
highrisk
aml
patient
ongo
target
therapi
tyrosin
kinas
inhibitor
may
also
relev
specif
case
preliminari
data
case
report
suggest
tyrosin
kinas
inhibitor
effect
posttranspl
set
particularli
patient
intern
tandem
duplic
may
consid
earli
use
new
therapeut
strategi
allogen
sct
alon
combin
pdli
order
enhanc
gvl
effect
patient
aml
primari
induct
failur
clofarabinebas
sequenti
reducedtox
condit
approach
seem
best
set
evalu
therapeut
strategi
order
minim
risk
cumul
toxic
sinc
phase
studi
limit
number
patient
enrol
preclud
realiz
subgroup
analys
evalu
impact
diseas
characterist
cytogenet
secondari
patient
outcom
note
despit
inclus
exclus
criteria
believ
popul
unselect
repres
popul
patient
refractori
aml
shown
inclus
major
patient
unfavor
cytogenet
patient
prolif
refractori
aml
howev
acknowledg
identifi
suitabl
donor
time
manner
may
difficult
patient
aggress
diseas
limit
access
transplant
use
haploident
donor
readili
avail
nearli
patient
may
promis
set
overal
view
result
current
prospect
multicent
studi
sequenti
condit
regimen
combin
clofarabin
aracbas
chemotherapi
follow
cyclophosphamid
iv
bulsufan
antithymocyt
globulinbas
ric
allogen
sct
appear
valid
approachplatform
patient
aml
primari
treatment
failur
regimen
repres
signific
improv
term
toxic
low
nrm
howev
relaps
remain
princip
complic
patient
collect
result
provid
framework
refin
sequenti
approach
design
improv
diseas
control
without
increas
toxic
although
approach
ideal
valid
phase
random
trial
choic
control
arm
mac
flamsa
reduc
toxic
regimen
may
tricki
final
approach
includ
enhanc
strategi
prevent
relaps
allogen
sct
